Aug 2026· Gynecologic Oncology Reports· Vol 66, pp. 102179· 0 citations· 16 references
Medicine
TL;DR
Folate receptor alpha expression in ovarian carcinomas is generally stable over time, with concordance observed in most paired specimens, however, discordance in approximately one-quarter of cases suggests spatial and/or temporal tumor heterogeneity.
Abstract
Background Folate receptor alpha (FRα) is frequently expressed in ovarian high-grade serous carcinomas and is a clinically actionable biomarker targeted by FDA-approved mirvetuximab soravtansine (MIRV) for platinum-resistant disease with high expression (≥75% of tumor cells with ≥2+ staining). However, longitudinal variability in FRα expression remains poorly understood. We evaluated temporal FRα expression changes in paired ovarian cancer specimens. Methods We performed a retrospective study of epithelial ovarian malignancies at Mayo Clinic Florida (2013–2025) in patients with ≥2 tumor specimens available. Tumors were classified as FRα-positive when ≥75% of viable tumor cells showed moderate-to-strong (2+ and/or 3+) staining and categorized as concordant or discordant based on changes in FRα status. Associations between clinicopathologic variables and FRα variability were evaluated using Fisher exact and Kruskal–Wallis tests. Results Sixty-six patients (median age 66 years), most with advanced-stage high-grade serous carcinoma (65/66), had paired tumor specimens. FRα expression was concordant in 77.3% of cases and discordant in 22.7%. Negative-to-positive conversion occurred more frequently than positive-to-negative conversion (16.7% vs 6.1%). No significant associations were identified between FRα variability and clinicopathologic factors, including age, grade, stage, treatment setting, prior chemotherapy exposure, MIRV use, specimen type, sampling site, baseline FRα expression, or timing intervals. In patients treated with neoadjuvant chemotherapy, negative-to-positive conversion was numerically more frequent, although not statistically significant (25% vs 9%; p = 0.479). Conclusions FRα expression in ovarian carcinomas is generally stable over time, with concordance observed in most paired specimens. However, discordance in approximately one-quarter of cases suggests spatial and/or temporal tumor heterogeneity.
To evaluate the clinical significance of folate receptor alpha (FRα) expression in endometrial serous carcinoma.
We retrospectively analyzed 47 patients with histopathologically confirmed endometrial serous carcinoma who underwent hysterectomy and received systemic therapy. FRα expression was assessed by i...
Teyfik Demir, Seda Nur Okur, Ayşe Rumeysa Aydoğan Demir et al.· BMC Cancer· 0 citations
Objectives: This study investigated the potential of folate receptor-positive circulating tumor cells (FR+CTCs) as a non-invasive biomarker for breast cancer diagnosis and clinical stratification. Materials and Methods: Between January 2024 and October 2024, 179 breast cancer patients and 38 patients with benign breast...
Juan Li, Jing Fu, Dan-Dan Zhang et al.· CytoJournal· 0 citations
Background: To study the expression and functional impact of PRs in ovarian cancers and to discuss the implications of PR positivity in ovarian cancer. Materials and Methods: Prospective observational study, conducted on 64 patients undergoing upfront primary surgery for ovarian cancers: 18-75 years of age. Data of pat...
Mariam anjum Ifthikar, Sanoor Neha Kamath, A. Rajanbabu et al.· Indian Journal of Obstetrics...· 0 citations
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, leaving limited targeted treatment options. In TNBC, TROP-2 (trophoblast cell surface antigen 2) is frequently overexpressed in TNBC and has been investigated...
Dalia Abd El-Kareem, Mostafa Mohamed Samy Salem, Zeinab A. Elshereef et al.· Scientific Journal of King F...· 0 citations
Objectives: Clusterin (CLU) has been implicated in cell survival and treatment resistance, but its relationship with pathological response to neoadjuvant chemotherapy in breast cancer remains unclear. We evaluated CLU expression in routine diagnostic specimens as a biomarker of pathological response and long-term outco...
M. García-Aranda, D. Martín-García, I. Zarcos-Pedrinaci et al.· Journal of Clinical Medicine· 0 citations